

1 **An *in silico* integrative analysis of hepatocellular carcinoma omics databases shows the dual**
2 **regulatory role of microRNAs either as tumor suppressors or as oncomirs**

3 **Mahmoud M. Tolba^{1,3} , Bangli Soliman^{2, 3}, Abdul Jabbar⁴, HebaT'Allah Nasser⁶,**
4 **Mahmoud Elhefnawi^{2, 3}**

5 ¹Pharmaceutical Division, Ministry of Health and Population, Faiyum, Egypt.

6 ²Biomedical Informatics and Chemoinformatics Group, Centre of Excellence for medical
7 research, National Research Centre, Cairo 12622, Egypt

8 ³Informatics and Systems Department, Division of Engineering research, National Research
9 centre, Cairo 12622, Egypt

10 ⁴ Department of Clinical Medicine, Faculty of Veterinary Science, University of Veterinary and
11 Animal Sciences, 54600, Lahore Punjab Pakistan

12 ⁵ Microbiology and Public Health Department, Faculty of Pharmacy and Drug Technology,
13 Heliopolis University, Cairo, Egypt

14 Corresponding author: Mahmoud M. Tolba

15 Email: mahmoud.tolba109@gmail.com

16

17 **Abstract:**

18 MicroRNAs are well known as short RNAs bases, 22 nucleotides, binding directly to
19 3'untranslated region (3'UTR) of the messenger RNA to repress their functions. Recently,
20 microRNAs have been widely used as a therapeutic approach for various types of Cancer.
21 MicroRNA is categorized into tumor suppressor and oncomirs. Tumor suppressor microRNAs
22 can repress the pathologically causative oncogenes of the hallmarks of Cancer. However, based
23 on the fact that miRNA has no proper fidelity to bind specific mRNAs due to binding to off-
24 targets, it results in a kind of inverse biological activity. Here, we have executed an *in-silico*
25 integrative analysis of GEO/TCGA-LIHC of genes/microRNAs expression analysis in HCC,
26 including (446 HCC vs. 146 normal specimens for miRNAs expression) ad 488 specimens for
27 genes expression. It virtually shows that microRNAs could have an ability to target both
28 oncogenes and tumor suppressor genes that contribute to its dual activity role as a tumor
29 suppressor and oncomirs via miRNA-lncRNA-TFs-PPI Crosstalk. Seven resultant microRNAs
30 show a putative dual role in HCC. It enhances our concluded suggestion of using combination
31 therapy of tumor suppressor genes activators with microRNAs.

32 **Keywords:** *in silico* tools; hepatocellular carcinoma; microRNAs

33 **1. Introduction**

34 Different types of Cancer are the lead diseases where the scientific community hunts for new
35 approaches to cure them. One of these approaches is epigenetic therapy [1]. Epigenetics is a
36 genetic field that strengthens our knowledge to comprehensively understand the factors that
37 control the genes translations within the cells [2]. Long non-coding RNAs, small interfering
38 RNA, and microRNAs are among these factors that control the translation of the genes [3-5].
39 This activity controls various biological processes such as cellular differentiation, cell signaling,
40 life span, and apoptosis. Cancer is a disease of deregulation of the normal state of biological
41 processes called cancer hallmarks [6].

42 Here we are focusing on Hepatocellular carcinoma (HCC), which is promptly considered one
43 of the most prevalent cancers worldwide [7-9]. With a rising rate, it is a prominent source of
44 mortality. Patients with advanced fibrosis, predominantly cirrhosis, and hepatitis B are
45 predisposed to developing HCC. Individuals with chronic hepatitis B and C infections are most
46 commonly suffering [10]. Different therapeutic options, including liver resection,
47 transplantation, systemic and local therapy, must be tailored to each patient [11]. One of the most
48 promising therapies for HCC is microRNAs therapy. It is well demonstrated that tens of
49 microRNAs have an ectopic expression in HCC. It directly correlates with the cancerous
50 pathway by inducing the list of oncogenes list with the cancerous cells. The therapeutic approach
51 by the restoration of microRNAs is inclined to suppress the oncogenes, decreasing Cancer [12].

52 **1.1 miRNAs**

53 MicroRNA dates back to the year 1993 as the first time the microRNAs term has been
54 enlightening. The first microRNA ever was c.elegan let 7. It regulates the c.elegan timing
55 development [13].

56 MicroRNAs are classes of non-coding RNAs that play an important role in gene expression
57 regulation in Cancer [14, 15]. They are generally transcribed from DNA sequences into primary
58 miRNA and processed into precursor miRNAs, and finally mature miRNAs [3]. The principal
59 role of microRNAs is to control protein translation by binding to complementary sequences in

60 the 3' untranslated region (UTR) of target messenger RNAs (mRNAs) and thus deleteriously
61 regulate mRNA translation. The microRNA–mRNA binding site is short (6–8 base pairs), and
62 then each microRNA has the prospective to target multiple different mRNAs [16, 17].


63 **1.2 MicroRNA Biogenesis**

64 MicroRNAs biosynthesis has been well studied. The more well-known biogenesis pathway is
65 the canonical pathway by which microRNAs are processed [18]. The canonical biogenesis
66 pathway can be described as follows: pri-microRNAs are transcribed from their genes. This
67 process into pri-miRNAs by microprocessor complex (RNA Binding protein DiGeorge
68 Syndrome Critical Region 8 (DGCR8) and a ribonuclease III enzyme, Drosha. DGCR8
69 recognizes an N6-methyladenylated GGAC and other motifs within the pri-miRNA, while
70 Drosha cleaves the pri-miRNA duplex at the base of the characteristic hairpin structure of pri-
71 miRNA. Accordingly, two nt 3' overhang on pre-miRNA is formed, one pre-miRNAs are
72 formed. They will be exported by exportin 5 (XPO5)/RanGTP complex and then processed by
73 the RNase III endonuclease Dicer. This processing includes terminal loop removal, and
74 consequently, immature miRNAs duplex is formed.

75 miRNA strand directionality determines the name of the mature form of miRNA. The 5p strand
76 arises from the 5-end from pre-miRNA hairpin, while the 3p strand originates from the 3-end .
77 The strands mentioned above were derived from the mature miRNA duplex, which can be loaded
78 into the Argonaute (AGO) family of proteins (AGO1-4 in humans) in an ATP-dependent
79 manner. For any given miRNA, this is a great difference between the proportional of AGO-
80 loaded 5p or 3p, which depends on the cell type or cellular environment. They may occur as one
81 more predominant than the other. The 5p or 3p strand selection is based on the thermodynamic
82 stability at the 5' ends of the miRNA duplex or a 5' U at nucleotide position1. Commonly, the
83 lower 5-strand or 5-uracil strand is likely loaded into AGO and estimated the guide strand. The
84 unloaded strand (passenger strand) is the unwanted strand from the guide strand through various
85 mechanisms depending on the complementarity degree. The microRNA passenger strand with no
86 mismatches is AGO2 sliced and cellular machinery degraded. Therefore, strong bias can be
87 produced. On the other hand, central mismatches miRNA duplexes or non-AGO2 loaded miRNA
88 are inertly unwound and degraded [19-21].

89 **1.3 Bioinformatics role in cancer therapy:**

90 Through Bioinformatics analysis of microarray and high through genomic data, hundreds of
91 ectopic expression of genes and microRNAs within various cancer types have been discovered
92 via free online Bioinformatics tools that play an effective role in predicting new targets for
93 microRNA and its genetic enrichment [22]. There are many free online tools [23] that show the
94 binding mode of tens of predicted genes for each microRNA, such as RNA22 [24], DIANA [25],
95 and miRanda [26]. It helps most in discovering new targets for the miRNAs for wet-lab
96 experiments. Here, multiple genes/microRNAs expression datasets have been used to uncover
97 the interaction of miRNAs with mRNAs, long non-coding RNA (LncRNA) [27], transcription
98 factors (TFs) [28], and protein-protein interaction (PPI) [29]. For miRNA-mRNA-LncRNA-TFs-
99 PPI crosstalk analysis, the followed work pipeline has helped most in putatively visualize all the
100 factors that may have a control on miRNAs path to be biologically active as oncomiR or tumor
101 suppressor as shown in the following flowchart (Figure 1).



102
103 Figure 1: Flowchart of the implemented workflow illustrates the methods that have been
104 followed.

105 A pool of the most differentially expressed miRs in HCC has been evolved and showed for their
106 involved actions in tumor development or progression. Interestingly in this context, our current
107 study will aim to perform a bioinformatics protocol on a huge list of the significantly down
108 expressed microRNAs within the HCC cells to unveil their activity role. It was found that one
109 microRNA has a potential role in working as a tumor suppressor and tumor activator for the
110 hallmarks of liver cancer.

111 2. Methodology

112 2.1 Collecting data of the significantly down-expressed microRNAs in HCC:

113 Using NCBI Pubmed <https://www.ncbi.nlm.nih.gov/pubmed/>, we have searched for all
114 published scientific articles and reviews working on microRNAs as a therapeutic approach for

115 liver cancer. We used "MicroRNA+Hepatocellular Carcinoma" as a query for our search. To
116 deepen our data, we utilized the PhenomiR [30] database to get all the microRNAs related to
117 Hepatocellular carcinoma.

118 To enrich our work, we have surveyed different registry of NCBI Gene Expression Omnibus
119 microarray databases for the miRs, and interestingly we have chosen five databases [31, 32] and
120 one TCGA LIHV –RNA seq databases with broad samples of 446 HCC vs. 146 adjacent normal
121 specimens which cover cirrhosis and G2/M phase of HCC.

122 These six integrated datasets are "Miltenyi Biotec miRXplore miRNA Microarray, GSE28854",
123 Capital Bio Mammalian miRNA Array Services V1 [1].0, GSE10694", "Affymetrix Multispecies
124 miRNA-2 Array, GSE74618"Affymetrix Multispecies miRNA-4 Array, GSE115016" "Agilent-
125 031181 Unrestricted_Human_miRNA_V16.0_Microarray, GSE110217" and "TCGA-LIHC,
126 RNA seq". These integrated datasets have been downloaded and analyzed by the Subio Platform
127 PC program <http://www.subio.jp/products/platform> to be filtered to get the overlap of common
128 down-expressed microRNAs in HCC specimens. The resultant list of the down-expressed
129 miRNAs, from datasets analysis, has been cross–confirmed by the previously mentioned manual
130 search within NCBI Pubmed and PhenomiR [33] .

131 **2.2 Collecting data of over-expressed genes in HCC:**

132 We have downloaded three integrated and recent datasets like miR datasets collection by
133 utilizing NCBI GEO microarray databases. They included the following " Affymetrix Human
134 Genome U133A 2.0 Array" GSE14520", "Affymetrix HT Human Genome U133A Array,
135 GSE14520" and TCGA- LIHC, and they have been conducted by subio platform program to get
136 the overexpressed genes in HCC.

137 **2.3 miRNAs-targets prediction**

138 First, an online miRBase database [34, 35] was used to get access to microRNAs. After that,
139 we have utilized miRWalk [36] to get the predicted and validated target genes of each
140 microRNA. Five different bioinformatics tools have been chosen to get the highest accuracy and
141 specificity for our predicted genes data. These five tools were miRANDA [26], DIANA [25],
142 RNAhybrid [37], targetscan [38] and RNA22 [24]. The validated miRNA targets by miRWalk

143 have been further enriched and confirmed via online experimental miRs-targets interaction
144 databases such as DIANA-TarBase v7.0 [39] and mirtarbase databases [40].

145 **2.4 Enrichment and gene ontology**

146 David functional annotation [41] was run to get biological processes and genes ontology of
147 each list of miRNA targets, which resulted from miRwalk. P-value < 0.05 was set as cut off of
148 the chosen biological process. The common resultant genes from datasets analysis by subio
149 platform and shown by miRwalk are enriched by David functional annotation.

150 The final step was data-filtration to highlight the biological process that is only related to
151 hepatocellular carcinoma hallmarks to show the impact of microRNAs as either tumor
152 suppressor or oncomiR. The previously filtrated genes have been used to draw a microRNAs-
153 targets network by Cytoscape [42] to show the transcriptomic level's miRs interactions.

154 **2.5 miRNA-lncRNA interaction**

155 miRNet online tool [43] was used to determine the regulatory interaction of microRNA-
156 LncRNA and microRNA-TFs interaction.

157 **2.6 miRNA-miRNA interaction**

158 TFmiR online tool [44] was used to get the regulatory roles of microRNA-microRNA
159 interaction. TFmiR is based on disease-specific microRNAs of putative miRNA-miRNA
160 regulations, PmmR database [45].

161 **2.7 miRNA- "Protein-Protein" interaction**

162 Differential gene expression (UP/down) has been used for PPI constructing network by
163 STRING v10 tool [46]. The Biological processes of the resultant network were filtrated into the
164 ones related to HCC. The genes incorporated in the output, Biological processes, were
165 reanalyzed via miRWalk to get down expressed miRNAs in HCC, correlated to these BPs.


166 **2.8 Free survival analysis**

167 Here, the aim is to visualize the potential impact of microRNA on the HCC survival
168 progression using GEPIA [47]. The selected genes on the central role of PPI by owning the
169 highest number of edges.

170 3. Results

171 3.1. MicroRNAs ectopic expression in HCC.

172 A list of 24 significantly down expressed microRNAs in HCC has been identified by Subio
173 platform PC for the overall six datasets, including GEO and TCGA-LIHC, RNA seq databases
174 (Figure 2). These down expressed microRNAs have been selected because they are common
175 among at least two datasets out of the six datasets. They have been further confirmed via the
176 PhenoMiR database (HCC).




177
178 Figure2: the down-expressed microRNAs in HCC, 24 microRNAs.

179 3.2. Expression of genes targeted by the microRNAs

180 As one of the main criteria for microRNA is that it is used as a gene therapy, the targeted
181 genes should be overexpressed within the HCC cell line. The overexpression of these genes
182 alters its function to be cancerous genes via inducing cancerous biological processes. Here, GEO
183 datasets and TCGA-LIHC database have been analyzed by subio platform to show the common
184 up-expressed genes in all datasets, combined to HCC target genes which have previously shown
185 by Disease-annotation of miRwalk for Hepatocellular carcinoma. It resulted in 180

186 overexpressed shared within," Affymetrix Human Genome U133A 2.0 Array" ' GSE14520",
187 "Affymetrix HT Human Genome U133A Array, GSE14520" and TCGA- LIHC (Figure 3 a & b).
188 Any gene, shown as down-expressed in HCC, has been excluded.

189



190


191 Figure 3: a) the differentially up-expressed genes in HCC

192

193

194

195




196

197 Figure 3: b) 180 genes are found to be common over-expression genes in HCC.

198 3.3. microRNAs-genes interactions.

199 Each microRNA of our 24 ones has hundreds of target genes resulted from an integrative
200 analysis of HCC gene expression datasets by subplatform (Figure 2), combined with resultant
201 genes from miRwalk related to HCC hallmarks, Disease-annotation of miRwalk for
202 Hepatocellular carcinoma has been implemented for search, as combinatorial targets
203 (supplementary 1). This analysis has evolved a list of HCC genes, further directed to determining
204 the expected Cytoscape networking with our 24 mirs. Interestingly, the regulatory network of 24
205 mirs with its target genes has been overviewed in (figure 4).




206


207 Figure4: A regulatory network of microRNAs, Red triangle, with their targets, drawn by
208 Cytoscape.

209 **3.4. Biological Process of microRNAs.**


210 It was unveiled that microRNA has a biological process related to tumor suppressor and tumor
211 activator (Figure 5).




212




213




214
215




216
217



218
219



220
221



222
223 Figure5: BP of target genes of down expressed miRs in HCC. Green bars show the tumor
224 suppressor activity of miRs. Red bars show their oncogenic activity.


225 Here, figure 4 shows a set of down-expressed microRNAs in HCC with their biological
226 process of the genes targeted by microRNA; only the BP of P -value < 0.05 has been selected.
227 The dual role of microRNA in HCC is evaluated by the impact of microRNA on BP of HCC
228 hallmarks either as an inducer or suppressor. The resultant is that each microRNA shows a dual
229 role, either tumor suppressor (green bars) or onco-miR (red bars).

230 3.5. miRNA-TFs regulatory role

231 Four microRNAs have been found with abundant TFs targets (Figure 6).

232

233



234
235 The figure 6: miRNA-TFs regulatory role.

236

237 Four microRNAs show tumor suppressor activity upon targeting TFs as transcriptional
238 regulatory factors as ant-apoptosis and proliferation regulation. Hence, repressing these TFs
239 results in tumor suppression, as shown in (table 1).

240 **Table 1:** shows Regulatory role of miRNA-TF interaction in HCC

MiRNA	TFs	Regulatory role of miRNA-TFs interaction in HCC
hsa-let-7c	AR,ESR1,EZH2,FOXO3,HOXA10,KHSR P,LIN28B,MYC,PRDM1,TRIM32	Tumor suppressor
hsa-mir-139	EZH2,JUN,REST,TP53	Tumor suppressor
hsa-mir-215	CDX1,TGFB1,TP53	Tumor suppressor
hsa-mir-223	CEBPB,DPF2,E2F1,HEY1,NFIA,NOTCH 1,NOTCH3 ,PRDM1,RELA,RUNX1,RUNX1T1,SPI1, TAL1,TWIST1	Tumor suppressor


241

242 **3.6. miRNA-LncRNA interaction**

243 Eight microRNAs have shown potential interaction with lncRNAs (Figure 7) (Table 2).

244 LncRNA acts as a CeRNA sponge for microRNA. Subsequently, it results in the excessive

245 inhibitory activity of miRNA-mRNA interaction by excessive down-expressing of miRNAs.



246
247 Figure 7: miRNA-lncRNA regulatory role.

248 **Table 2:** shows Regulatory role of Therapeutic effect of microRNA-lncRNA on HCC

microRNA	LncRNA	Therapeutic effect of microRNA-lncRNA on HCC.
hsa-let-7c	AC074117.10,AC105760.2,CASP8AP2,CDKN2B-AS1,CTA-204B4.6,CTD-2270L9.5,CTD-3138B18.5,HOXA11-AS,KCNQ1OT1,LINC00263,LINC00665,MIR4720,NEAT1,NUTM2	Onco-miR

A-AS1,PTCHD3P1,RP11-1103G16.1,RP11-197N18.2,RP11-214O1.2,RP11-264B17.3,RP11-277P12.20,RP11-27I1.2,RP11-282O18.6,RP11-452L6.5,RP11-457M11.2,RP11-473I1.10,RP11-492E3.1,RP11-498P14.3,RP11-727A23.5,RP11-819C21.1,RP11-834C11.4,RP11-923I11.1,RP11-996F15.2,RP13,507I23.1,SCARNA10,TTY15,UBXN8,XIST,XXba
c-BPG300A18.13,ZNF518A

hsa-mir-122-5p	AC005154.5, AC084ASB16-AS1,CDKN2B-AS1,CTA-204B4.6,CTC-503J8.6,CTD-2517M14.5, MAL2,MIR3179-1,MIR3179-2,PCBP1-AS1,RP11-290F20.1,RP11-518L10.2,RP11-571M6.18,RP6-24A23.7,SNHG7,VP S11	Onco-miR
hsa-mir-130a-3p	AC007038.7,AC007040.7,AC084018.1,AC084219.4,AC135048.13,AP001065.15,BOLA3-AS1,CCAT1,CTA-204B4.6,CTB-92J24.2,CTC-281B15.1,CTD-2369P2.2,CTD-3092A11.2,FGD5-AS1,H19,HOTAIR,HOXA11-AS,HOXD-AS1,KCNQ1OT1,LINC00116,LINC00339,LINC00667,LINC00839,MAP3K14,MIR17HG,NUTM2A-AS1,PRKCQ-AS1,RP11-197P3.5,RP11-290D2.4,RP11-344B2.2,RP11-355O1.11,RP11-361F15.2,RP11-363E7.4,RP11-429J17.6,RP11-588K22.2,RP11-656D10.3,RP11-73M18.8,RP1-178F10.3,RP11-84C13.1,RP13-638C3.2,RP4-639F20.3,SEC22B,SLC26A4-AS1,TMEM161B-AS1,XIST,ZNRD1-AS1	Onco-miR
hsa-mir-145-5p	AC016683.6,AC069513.3,AC142401.2,AL589743.1,C17orf76-AS1,CTA-204B4.6,CTD-2116N17.1,CTD-2516F10.2,GS1-251I9.4,HNRNPU-AS1,hsa-mir-132,IQCH-AS1,JPX,KCNQ1OT1,LINC00707,LINC00852,MAL2,MALAT1,MAPKAPK5-AS1,RP11-115D19.1,RP11-156E6.1,RP11-214C8.5,RP11-344E13.3,RP11-478C19.2,RP11-705C15.3,RP11-74E22.3,RP11-793H13.8,RP1-37E16.12,SCARNA10,SNHG1,TUG1,UHRF1	Onco-miR
hsa-mir-195-5p	AC003092.1,AC003104.1,AC004383.4,AC005154.5,AC005154.6,AC005537.2,AC005562.1,AC011893.3,AC016629.8,AC074093.1,AC084219.4,AC090587.2,AC091878.1,AC108142.1,AC113189.5,AP000721.4,AP001065.2,C14orf169,C1RL-AS1,CERS6-AS1,CTA-204B4.6,CTB-50E14.6,CTB-89H12.4,CTBP1-AS1,CTC-228N24.3,CTC-246B18.8,CTC-429P9.3,CTC-444N24.11,CTD-2201E18.3,CTD-2339L15.3,CTD-2516F10.2,CTD-2574D22.4,CWC15,DCP1A,DLG1-AS1,DLX6-AS1,EPB41L4A-AS1,ERI3-IT1,ERVK13-1,FENDRR,FGD5-AS1,GS1-124K5.11,GS1-358P8.4,HCG17,HCG18,IQCH-AS1,KIF9-AS1,LA16c306E5.2,LINC00094,LINC00176,LINC00339,LINC00473,LINC00511,LINC00649,LINC00662,LINC00707,LL22NC03-N27C7.1,MCM3AP-AS1,MEG8,MIR497HG,NUTM2A-AS1,PDXDC2P,PVT1,RASAL2-AS1,RP11-1103G16.1,RP11-	Onco-miR


hsa-mir-223	125K10.4,RP11-155D18.12,RP11-159D12.9,RP11-169K16.9,RP11-16E12.2,RP11-18A3.4,RP11-204M4.2,RP11-216F19.2,RP11-218M22.1,RP11-21N3.1,RP11-244H3.1,RP11-244O19.1,RP11-277L2.2,RP11-27I1.2,RP11-282K24.3,RP11-2C24.4,RP11-329L6.1,RP11-361F15.2,RP11-379K17.11,RP11-383C5.4,RP11-383J24.5,RP11-384K6.6,RP11-38J22.6,RP11-390P2.4,RP11-403I13.4,RP11-43D2.6,RP11-453E17.1,RP11-461L13.3,RP11-464F9.1,RP11-467L20.9,RP11-474P12.5,RP11-477D19.2,RP11-506M13.3,RP11-540O11.1,RP11-543D5.2,RP11-549J18.1,RP11-54O7.1,RP11-588K22.2,RP11-60I3.5,RP11-64K12.2,RP11-66B24.4,RP11-677M14.3,RP11-690G19.3,RP11-697M17.1,RP11-773D16.1,RP11-869B15.1,RP11-91G21.2,RP11-923I11.1,RP11-96D1.10,RP11-973H7.2,RP11-983P16.4,RP1-283E3.8,RP1-310O13.12,RP13-507I23.1,RP3-341D10.4,RP3-486L4.3,RP4-614O4.11,RP4-773N10.5,RP5-1028K7.2,RP5-1148A21.3,RP5-1172N10.3,RP5-1180C10.2,RP5-955M13.3,RP6-206I17.2,RP6-24A23.7,SCGB1B2P,SEMA3B,SENP3-EIF4A1,SLC37A4,SNHG1,SNHG12,SNHG16,SPPL2B,TRAF3IP2-AS1,TTN-AS1,XIST,XXbac-B461K10.4,XXbac-BPG32J3.20,ZNF518A,ZNRD1-AS1,AC006262.5 AC006262.5,AP001172.2,C17orf76-AS1,CTB-89H12.4,CTC-444N24.11,CTC-479C5.10,FGD5-AS1,GAS5,HOXA11-AS,INTS6-AS1,LINC00846,MAGI2-AS3,MIR155HG,MIR17HG,OIP5-AS1,PITPNA-AS1,POLDIP2,RP11-284N8.3,RP11-403I13.8	Onco-miR
hsa-mir-29c-3p	AC005154.5,AC005154.6,AC007036.5,AC012146.7,AP000304.2,CTD-2116N17.1,CTD-2339L15.1,CTD-2517M14.5,EMG1,GAS5,GS1-124K5.11,H19,HCP5,HOXA-AS3,HOXA-AS4,KCNQ1OT1,LIFR-AS1,LINC00338,LINC00511,MIAT,MLLT4-AS1,OIP5-AS1,RP11-145M9.4,RP11-216F19.2,RP11-220I1.1,RP11-227G15.3,RP11-280F2.2,RP11-290F20.1,RP11-303E16.8,RP11-311C24.1,RP11-347I19.3,RP11-373L24.1,RP11-429J17.2,RP11-467L20.9,RP11-480D4.3,RP11-615I2.7,RP11-618G20.1,RP11-690G19.3,RP4-665N4.8,RP5-837J1.2,SETD5-AS1,SIK3-IT1,SPPL2B,TUG1,U47924.19,XIST,ZNF518A,ZNF761	Onco-miR
hsa-mir-497-5p	AC003092.1,AC003104.1,AC004383.4,AC005154.5,AC005154.6,AC005537.2,AC005562.1,AC011893.3,AC016629.8,AC074093.1,AC084219.4,AC090587.2,AC091878.1,AC108142.1,AC113189.5,AP000721.4,AP001065.2,C14orf169,C1RL-AS1,CERS6-AS1,CTA-204B4.6,CTB-50E14.6,CTB-89H12.4,CTBP1-AS1,CTC-228N24.3,CTC-246B18.8,CTC-429P9.3,CTC-444N24.11,CTD-2201E18.3,CTD-2339L15.3,CTD-2516F10.2,CTD-2574D22.4,CWC15,DCP1A,DLG1-AS1,DLX6-AS1,EPB41L4A-AS1,ERI3-IT1,ERVK13-1,FENDRR,FGD5-AS1,GS1-124K5.11,GS1-358P8.4,HCG17,HCG18,IQCH-AS1,KIF9-AS1,LA16c306E5.2,LINC00094,LINC00176,LINC00339,LINC00473,LINC00511,LINC00649,LINC00662,LINC00707,LL22NC03-	Onco-miR

N27C7.1,MCM3AP-AS1,MEG8,MIR497HG,NUTM2A-AS1,PDXDC2P,PVT1,RASAL2-AS1,RP11-1103G16.1,RP11-125K10.4,RP11-155D18.12,RP11-159D12.9,RP11-169K16.9,RP11-16E12.2,RP11-18A3.4,RP11-204M4.2,RP11-216F19.2,RP11-218M22.1,RP11-21N3.1,RP11-244H3.1,RP11-244O19.1,RP11-277L2.2,RP11-27I1.2,RP11-282K24.3,RP11-2C24.4,RP11-329L6.1,RP11-361F15.2,RP11-379K17.11,RP11-383C5.4,RP11-383J24.5,RP11-384K6.6,RP11-38J22.6,RP11-390P2.4,RP11-403I13.4,RP11-43D2.6,RP11-453E17.1,RP11-461L13.3,RP11-464F9.1,RP11-467L20.9,RP11-474P12.5,RP11-477D19.2,RP11-506M13.3,RP11-540O11.1,RP11-543D5.2,RP11-549J18.1,RP11-54O7.1,RP11-588K22.2,RP11-60I3.5,RP11-64K12.2,RP11-66B24.4,RP11-677M14.3,RP11-690G19.3,RP11-697M17.1,RP11-773D16.1,RP11-869B15.1,RP11-91G21.2,RP11-923I11.1,RP11-96D1.10,RP11-973H7.2,RP11-983P16.4,RP1-283E3.8,RP1-310O13.12,RP13-507I23.1,RP3-341D10.4,RP3-486L4.3,RP4-614O4.11,RP4-773N10.5,RP5-1028K7.2,RP5-1148A21.3,RP5-1172N10.3,RP5-1180C10.2,RP5-955M13.3,RP6-206I17.2,RP6-24A23.7,SCGB1B2P,SEMA3B,SENP3-EIF4A1,SLC37A4,SNHG1,SNHG12,SNHG16,SPPL2B,TRAF3IP2-AS1,TTN-AS1,XIST,XXbac-B461K10.4,XXbac-BPG32J3.20,YLPM1,ZNF518A,ZNRD1-AS1

249

250 3.7. miRNA-miRNA interaction

251 Here, it is predicted shown that microRNA are acting as ceRNA for each other's (Figure 8).




252

253 Figure 8: miRNA-miRNA, PmmR, regulatory interactions with 10 nodes and 19 edges. Here, all
254 the input microRNAs are supposed to be therapeutically tumor suppressor. However, these
255 microRNAs acts as a sponge to each other. Consequently, it is putative that this kind of
256 interaction results in an oncogenic impact.


257 It results in enhancing microRNA regulatory role as tumor suppressor (Fig.7). Seven
258 miRs show ceRNAs activity.miR-214 acts as sponge for (miR-125a, miR-99a, miR-139, miR-
259 125b).miR -125a acts as sponge for miR-99a.miR- 99a acts as sponge for let -7c.miR-130a acts
260 as sponge for (let-7c, mir-99a).miR 195 acts as sponge for (let-7c, miR-99a).miR-497 acts as
261 sponge for (let-7c, miR-99a).

262 **3.8. microRNA-PPI interaction**


263 Six major biological processes in HCC were resultants (Figure 9). These BP are GO:0051726
264 regulation of cell cycle, GO:0071158 positive regulation of cell cycle arrest, GO:1901991
265 negative regulation of mitotic cell cycle phase transition, GO:0040008 regulation of growth,
266 GO:0042981 regulation of the apoptotic process, GO:0043066: Negative regulation of the
267 apoptotic process. As shown in table 3, GO:0051726 (regulation of cell cycle) BP has 30 genes
268 as targets for ten down expressed miRNAs in HCC. Because activation of the cell cycle is one of
269 the major hallmarks of liver cancer. Hence, suppressing the cell cycle by miRNAs results in
270 considering that activity as miRNA tumor suppressor. On the other hand, GO:0071158 (positive
271 regulation of cell cycle arrest), GO:1901991 (negative regulation of mitotic cell cycle phase
272 transition), GO:0042981 (regulation of apoptotic process) BPs have 7, 15, 27 genes,
273 respectively, which are non-incorporated in HCC. It is because GO:0071158, GO:1901991, and
274 GO:0042981 BPs are not hallmarks of causing liver cancer. Therefore, suppression of
275 GO:0071158 by miRNAs results in oncogenic aspects.




GO:0051726 regulation of cell cycle



GO:0043066 Negative regulation of apoptotic process




GO:0071158 positive regulation of cell cycle arrest




279

GO:1901991 negative regulation of mitotic cell cycle phase transition



280

GO:0042981 regulation of apoptotic process



281

GO:0040008 regulation of growth

282 Figure 9 shows biological processes retrieved from PPI network of 180 overexpressed genes and
 283 572 down expressed genes in HCC.PPI network was analyzed by STRING.

284 **Table 3:** Illustration of the Biological process of PPI network and their matched microRNAs

Biological Process	microRNAs	Gene Target	Therapeutic effect of microRNA-PPI on HCC.
GO:0051726 regulation of cell cycle	hsa-mir-30a-5p hsa-mir-130a-3p hsa-miR-30e-5p hsa-mir-497-5p sa-mir-122-5p hsa-mir-223 hsa-let-7c hsa-mir-215	CDC7, DTL, PCNA RACGAP1 CDC7 BIRC5, CDK1, RACGAP1 BIRC5 CDK2,ECT2,E2F8,E2F8,E2F8,PLCB1 CKS2 CDC7,CDKN2A,DTL,E2F8,ECT2,FEN1,GPSM2	Tumor supressor
GO:0071158 positive regulation of cell cycle arrest	hsa-mir-195-5p hsa-mir-125b-5p	KIF14,MAD2L1,PSRC1,RACGAP1 BIRC5,CDK1 CDKN2A	Onco-miR
GO:1901991 negative regulation of mitotic cell cycle phase transition		AURKA,BIRC5,BLM,BUB1,BUB1B,CCNB1,CENPF,E2F8,EZH2,GTSE1,MAD2L1,PCNA,SFN,TRIP13,TTK	Onco-miR
GO:0040008 regulation of growth		ACSL4,CCNB1,CCNB2,CDKN2A,CDKN2C,FOXM1,G6PD,GPC3,KIF14,NDRG3,PLCB1,PSRC1,SFN,SMARCA4,SPP1,TKT	Tumor supressor
GO:0042981 regulation of apoptotic process		AKR1C3,ASNS,AURKA,BARD1,BIRC5,CDKN2A,DLG5,ECT2,G6PD,HMGB2,ID1,IRAK1,ITGA6,KIF14,MAD2L1,MDK,MELK,MMP9,NME1,NQO1,PEA15,ROBO1,SFN,SORT1,STIL, TOP2A,TP53I3	Onco-miR

GO:0043066:

Negative regulation of apoptotic process

of hsa-mir-145-5p
hsa-mir-122-5p
hsa-mir-375


ACAA2,ANGPTL4,ATF5,AXL,C8orf4,CAT,CC
L19,CCL2,CCL21,CCL5,CNTFR,CTH,CXCL12,
CYR61,DOCK8,DUSP1,EDNRB,FABP1,FAM13
4B,FGA,FGB,FGFR2,FGG,FHL2,HAND2,HCLS
1,HGF,HHIP,ID1,IGF1,IL7R,NAT8,NGFR,NTF3
,PDK4,PKHD1,PLAC8,PPARGC1A,PTGS2,RG
N,SERPINB9,SERPINE1,SOCS2,SPRY2,TEK,T
HBS1,VNN1
SERPINE1
AXL, FHL2
AXL

Tumor suppressor

285


286 3.9. Free survival analysis

287 Here, survival analysis shows us that ectopic expression of (CCNB1, AURKA, BIRC5,
288 HGF, IGF1, TOP2A) has poor survival progression in the long term in LIHC(Figure 10). It
289 means that microRNA acting on these genes is non-additive value for curing HCC in the long
290 term.




291 1.


292



293
294



295
296



297
298

Figure 10: list of survival figures of the gene target.

299 **4. Discussion**

300 MicroRNAs are a promising therapeutic gene therapy for Cancer (Table 4).

301 **Table 4:** list of miRNAs as HCC therapy.

MicroRNA	Target	Pathway	Suppression or Activation activity of miRNA
miR-142	TGF-Beta	mTOR	Suppression
miR-199b-5p	TGF-Beta 1		
mir-139-5p	PDK1		
miR-223	Rab1		
miR-195	AEG-1	Wnt signaling	Suppression
miR-214-3p	PIM-1	JAK-STAT	Suppression

mIR-200	Pin1		
miR-199a-5p	MAP4K3		
miR-143	GATA6	MAPK cascade	Suppression
miR-125A	MMP11,SIRT7		
miR-200a	GAB1		

302
303 They are involved in regulating many biological processes. Their ability to bind with 3' un-
304 translated region of mRNAs recruit many factors to degrade mRNAs , consequently acting as a
305 repressor for oncoprotein synthesis [48, 49] . It results in knocking down the pathologically
306 causative genes of Cancer [50] (Table 3). However, they have putatively mysterious functions of
307 acting through inversely dual role either as a tumor suppressor or oncomiR. Through our current
308 work, we tried to uncover the dual role of a set of microRNAs in HCC. MicroRNAs, on the
309 contrary to siRNAs, lack specificity to bind mRNAs, where MicroRNAs have binding seed
310 regions with a high capacity to target multiple genes [51]. It is considered a drawback in
311 microRNAs as an approach to gene therapy. It is experimentally invalid to target specific
312 oncogenes to be knocked down by microRNA where microRNAs target tumor suppressor genes,
313 off-targets, that result in activating cancerous biological processes. To uncover these dually
314 mysterious microRNA functions, we have collected the common down- expressed genes of
315 miRNAs HCC within different GEO and TCGA-LIHC databases. The chosen databases are for
316 (HCC vs. cirrhotic non-cancer) and (G2/M phase of the cell cycle in vs. normal tissues) to cover
317 different pathological stages of HCC.


318 Additionally, these datasets cover broad samples (446 HCC vs. 146 normal specimens).In this
319 respect, we targeted only the microRNAs common in all the chosen datasets due to the
320 inconsistency of the results as miRNA measurement technology is immature compared to gene
321 expression's system where CapitalBio's is the least reliable dataset. Milteny's and TCGA's
322 datasets generated the most consistent results. Affymetrix's arrays are weak in detecting the
323 expression difference. Hence, we decided to integrate these datasets to get the common down-
324 expressed miRNAs to ensure accuracy.

325 Our work aims to support the combinatorial therapy of microRNA. One technique activates
326 the tumor suppressor genes, off-target genes, via designing a cassette of miRNA-guide RNA-
327 CRISPR/Cas9 [52]. Maybe CRISPRa is a choice to be combined with microRNA to activate

328 these off-targets genes knocked down by microRNAs. An additional suggestion is to combine
329 microRNA with an exogenous expression vector carrying the tumor suppressor genes. Also,
330 combined tumor suppressor microRNA with those microRNAs that activate tumor suppressor
331 genes via binding its 5'UTR is a third way to solve the drawback of microRNAs' dual role [53].
332 The idea behind our suggested combinatorial therapy is that it helps most in increasing the level
333 of expressed tumor suppressor genes within the cells.

334 Moreover; microRNA cocktail therapy should not be a combination of microRNAs which act as
335 CeRNA for each other [54]. One example of the dual role of microRNAs is "how microRNAs
336 regulate dually in colorectal cancer?"; It was reported that miRNAs show dual regulatory roles in
337 colorectal Cancer [55]. In a wet lab, much microRNAs act dually. miR-375 shows dual
338 functions in prostate cancer [56]. In Breast cancer, miR-181a acts as an onco-miR via targeting
339 Bax, increasing metastasis. On the other hand, it acts as a tumor suppressor via targeting BCL-
340 increasing apoptosis [57].

341 The final regulatory role of microRNA is evaluated by miRNA-LncRNA-mRNA-TFs
 342 Crosstalk as an accumulative impact on how microRNA acts (Figure 11).



343
 344 Figure11: Regulatory role of microRNA as either oncomiR and/ or tumor suppressor miR.

345 LncRNA is 200 nt, acting as epigenetic regulators and as competing RNA for microRNA.
 346 It results in decreasing in the affinity of microRNA to be available for mRNA. Subsequently, it is
 347 predicted to alter microRNA regulatory role shifting it to be oncomiR for down expressed
 348 miRNAs in Cancer. On the other hand, transcription factors act via either activator or suppressor

349 for the genes. So, microRNA acting on TFs results in either enhancing its tumor suppressor
350 activity or shifting into being oncomiR. It is based on the ontology of the gene where TF targets.

351 Through our work, we concluded that microRNAs are incorporated in most hallmarks of
352 hepatocellular carcinoma. However, these microRNAs' dual activity made the consideration of
353 the dominance of one of both functions a tough decision. Hence, we strongly suggest that more
354 investigations on the factors that affect which microRNA function types will predominate should
355 be carried out to solve their Myth. We suggest enhancing the protocols of using microRNAs as a
356 gene therapy by combing activating techniques with miRs. These activating techniques are to
357 induce the tumor suppressor genes targeted by microRNAs.

358 **Conflict of Interest**

359 The authors declare that there are no conflicts of interest regarding the publication of this paper.

360 **Authors' Contributions**

361 Mahmoud M. Tolba, Bangli Soliman and Mahmoud Elhefnawi designed this project. Mahmoud
362 M. Tolba and HebaT'Allah Nasser conducted the reseach. Mahmoud M. Tolba, Abdul Jabbar
363 edited the manuscript. Mahmoud M. tolba designed the figures.

364

365 **References**

- 366 1. A. Roberti, A. F. Valdes, R. Torrecillas, M. F. Fraga and A. F. J. C. e. Fernandez, "Epigenetics
367 in cancer therapy and nanomedicine," vol. 11, no. 1, pp. 1-18, 2019.
- 368 2. S. Heerboth, K. Lapinska, N. Snyder, M. Leary, S. Rollinson and S. Sarkar, "Use of epigenetic
369 drugs in disease: an overview. Genet Epigenet. 2014; 6: 9–19," Ed.
- 370 3. J. O'Brien, H. Hayder and Y. Zayed, "Overview of microRNA biogenesis, mechanisms of
371 actions, and circulation, Front. Endocrinol., 2018, vol. 9, no. 402," Ed., 2018.
- 372 4. A. Wittrup and J. J. N. R. G. Lieberman, "Knocking down disease: a progress report on siRNA
373 therapeutics," vol. 16, no. 9, pp. 543-552, 2015.
- 374 5. R.-W. Yao, Y. Wang and L.-L. J. N. c. b. Chen, "Cellular functions of long noncoding RNAs,"
375 vol. 21, no. 5, pp. 542-551, 2019.
- 376 6. Y. A. Fouad and C. J. A. j. o. c. r. Aanei, "Revisiting the hallmarks of cancer," vol. 7, no. 5,
377 pp. 1016, 2017.
- 378 7. N. M. Tunissiolli, M. M. U. Castanhole-Nunes, P. M. Biselli-Chicote, É. C. Pavarino and R. F.
379 J. A. P. j. o. c. p. A. da Silva, "Hepatocellular carcinoma: a comprehensive review of biomarkers,
380 clinical aspects, and therapy," vol. 18, no. 4, pp. 863, 2017.
- 381 8. T. El Jabbour, S. M. Lagana and H. J. W. j. o. g. Lee, "Update on hepatocellular carcinoma:
382 Pathologists' review," vol. 25, no. 14, pp. 1653, 2019.

- 383 9. P. Golabi, S. Fazel, M. Otgonsuren, M. Sayiner, C. T. Locklear and Z. M. J. M. Younossi,
384 "Mortality assessment of patients with hepatocellular carcinoma according to underlying disease
385 and treatment modalities," vol. 96, no. 9, 2017.
- 386 10. L. P. Waller, V. Deshpande and N. J. W. j. o. h. Pysopoulos, "Hepatocellular carcinoma: A
387 comprehensive review," vol. 7, no. 26, pp. 2648, 2015.
- 388 11. D. Dimitroulis, C. Damaskos, S. Valsami, S. Davakis, N. Garmpis, E. Spartalis, A.
389 Athanasiou, D. Moris, S. Sakellariou and S. J. W. j. o. g. Kykalos, "From diagnosis to treatment
390 of hepatocellular carcinoma: An epidemic problem for both developed and developing world,"
391 vol. 23, no. 29, pp. 5282, 2017.
- 392 12. F. Vasuri, M. Visani, G. Acquaviva, T. Brand, M. Fiorentino, A. Pession, G. Tallini, A.
393 D'Errico and D. J. W. j. o. g. de Biase, "Role of microRNAs in the main molecular pathways of
394 hepatocellular carcinoma," vol. 24, no. 25, pp. 2647, 2018.
- 395 13. R. C. Lee, R. L. Feinbaum and V. J. c. Ambros, "The *C. elegans* heterochronic gene *lin-4*
396 encodes small RNAs with antisense complementarity to *lin-14*," vol. 75, no. 5, pp. 843-854,
397 1993.
- 398 14. H. Ling, M. Fabbri and G. A. J. N. r. D. d. Calin, "MicroRNAs and other non-coding RNAs
399 as targets for anticancer drug development," vol. 12, no. 11, pp. 847-865, 2013.
- 400 15. K. Felekis, E. Touvana, C. Stefanou and C. J. H. Deltas, "microRNAs: a newly described
401 class of encoded molecules that play a role in health and disease," vol. 14, no. 4, pp. 236, 2010.
- 402 16. F. Zhang and D. J. G. Wang, "The pattern of microRNA binding site distribution," vol. 8, no.
403 11, pp. 296, 2017.
- 404 17. K. C. Miranda, T. Huynh, Y. Tay, Y.-S. Ang, W.-L. Tam, A. M. Thomson, B. Lim and I. J.
405 C. Rigoutsos, "A pattern-based method for the identification of MicroRNA binding sites and
406 their corresponding heteroduplexes," vol. 126, no. 6, pp. 1203-1217, 2006.
- 407 18. M. M. Chong, G. Zhang, S. Cheloufi, T. A. Neubert, G. J. Hannon, D. R. J. G. Littman and
408 development, "Canonical and alternate functions of the microRNA biogenesis machinery," vol.
409 24, no. 17, pp. 1951-1960, 2010.
- 410 19. L.-A. MacFarlane and P. J. C. g. R. Murphy, "MicroRNA: biogenesis, function and role in
411 cancer," vol. 11, no. 7, pp. 537-561, 2010.
- 412 20. J. O'Brien, H. Hayder, Y. Zayed and C. J. F. i. e. Peng, "Overview of microRNA biogenesis,
413 mechanisms of actions, and circulation," vol. 9, pp. 402, 2018.
- 414 21. J. Krol, I. Loedige and W. J. N. R. G. Filipowicz, "The widespread regulation of microRNA
415 biogenesis, function and decay," vol. 11, no. 9, pp. 597-610, 2010.
- 416 22. G. J. Gordon, *Bioinformatics in cancer and cancer therapy*, Springer Science & Business
417 Media, 2008.
- 418 23. Á. L. Riffo-Campos, I. Riquelme and P. J. I. j. o. m. s. Brebi-Mieville, "Tools for sequence-
419 based miRNA target prediction: what to choose?," vol. 17, no. 12, pp. 1987, 2016.
- 420 24. P. Loher and I. J. B. Rigoutsos, "Interactive exploration of RNA22 microRNA target
421 predictions," vol. 28, no. 24, pp. 3322-3323, 2012.
- 422 25. I. S. Vlachos and A. G. Hatzigeorgiou, "Functional analysis of miRNAs using the DIANA
423 tools online suite," in *Drug Target miRNA*, Ed., pp. 25-50, Springer, 2017.
- 424 26. D. Betel, A. Koppal, P. Agius, C. Sander and C. J. G. b. Leslie, "Comprehensive modeling of
425 microRNA targets predicts functional non-conserved and non-canonical sites," vol. 11, no. 8, pp.
426 1-14, 2010.
- 427 27. J. Jarroux, A. Morillon and M. J. L. N. C. R. B. Pinskaya, "History, discovery, and
428 classification of lncRNAs," pp. 1-46, 2017.

- 429 28. T. Mitsis, A. Efthimiadou, F. Bacopoulou, D. Vlachakis, G. P. Chrousos and E. J. W. A. o. S.
430 J. Eliopoulos, "Transcription factors and evolution: an integral part of gene expression," vol. 2,
431 no. 1, pp. 3-8, 2020.
- 432 29. S. A. J. B. Teichmann, "Principles of protein-protein interactions," vol. 18, no. suppl_2, pp.
433 S249-S249, 2002.
- 434 30. J. B. Berletch, F. Yang and C. M. J. G. b. Disteché, "Escape from X inactivation in mice and
435 humans," vol. 11, no. 6, pp. 1-7, 2010.
- 436 31. E. Clough and T. Barrett, "The gene expression omnibus database," in *Statistical genomics*,
437 Ed., pp. 93-110, Springer, 2016.
- 438 32. Barrett T. Gene Expression Omnibus (GEO) 2013 May 19. In: The NCBI Handbook
439 [Internet]. 2nd edition. Bethesda (MD): National Center for Biotechnology Information (US);
440 2013-. "<https://www.ncbi.nlm.nih.gov/books/NBK159736/>."
- 441 33. A. Ruepp, A. Kowarsch, D. Schmidl, F. Buggenthin, B. Brauner, I. Dunger, G. Fobo, G.
442 Frishman, C. Montrone and F. J. J. G. b. Theis, "PhenomiR: a knowledgebase for microRNA
443 expression in diseases and biological processes," vol. 11, no. 1, pp. 1-11, 2010.
- 444 34. S. Griffiths-Jones, H. K. Saini, S. Van Dongen and A. J. J. N. a. r. Enright, "miRBase: tools
445 for microRNA genomics," vol. 36, no. suppl_1, pp. D154-D158, 2007.
- 446 35. A. Kozomara and S. J. N. a. r. Griffiths-Jones, "miRBase: integrating microRNA annotation
447 and deep-sequencing data," vol. 39, no. suppl_1, pp. D152-D157, 2010.
- 448 36. H. Dweep, C. Sticht, P. Pandey and N. J. J. o. b. i. Gretz, "miRWalk–database: prediction of
449 possible miRNA binding sites by “walking” the genes of three genomes," vol. 44, no. 5, pp. 839-
450 847, 2011.
- 451 37. J. Krüger and M. J. N. a. r. Rehmsmeier, "RNAhybrid: microRNA target prediction easy, fast
452 and flexible," vol. 34, no. suppl_2, pp. W451-W454, 2006.
- 453 38. B. Fromm, T. Billipp, L. E. Peck, M. Johansen, J. E. Tarver, B. L. King, J. M. Newcomb, L.
454 F. Sempere, K. Flatmark and E. J. A. r. o. g. Hovig, "A uniform system for the annotation of
455 vertebrate microRNA genes and the evolution of the human microRNAome," vol. 49, pp. 213-
456 242, 2015.
- 457 39. I. S. Vlachos, M. D. Paraskevopoulou, D. Karagkouni, G. Georgakilas, T. Vergoulis, I.
458 Kanellos, I.-L. Anastasopoulos, S. Maniou, K. Karathanou and D. J. N. a. r. Kalfakakou,
459 "DIANA-TarBase v7. 0: indexing more than half a million experimentally supported miRNA:
460 mRNA interactions," vol. 43, no. D1, pp. D153-D159, 2015.
- 461 40. H.-Y. Huang, Y.-C.-D. Lin, J. Li, K.-Y. Huang, S. Shrestha, H.-C. Hong, Y. Tang, Y.-G.
462 Chen, C.-N. Jin and Y. J. N. a. r. Yu, "miRTarBase 2020: updates to the experimentally validated
463 microRNA–target interaction database," vol. 48, no. D1, pp. D148-D154, 2020.
- 464 41. B. T. Sherman and R. A. J. N. p. Lempicki, "Systematic and integrative analysis of large
465 gene lists using DAVID bioinformatics resources," vol. 4, no. 1, pp. 44, 2009.
- 466 42. P. Shannon, A. Markiel, O. Ozier, N. S. Baliga, J. T. Wang, D. Ramage, N. Amin, B.
467 Schwikowski and T. J. G. r. Ideker, "Cytoscape: a software environment for integrated models of
468 biomolecular interaction networks," vol. 13, no. 11, pp. 2498-2504, 2003.
- 469 43. Y. Fan, K. Siklenka, S. K. Arora, P. Ribeiro, S. Kimmins and J. J. N. a. r. Xia, "miRNet-
470 dissecting miRNA-target interactions and functional associations through network-based visual
471 analysis," vol. 44, no. W1, pp. W135-W141, 2016.
- 472 44. M. Hamed, C. Spaniol, M. Nazarieh and V. J. N. a. r. Helms, "TFmiR: a web server for
473 constructing and analyzing disease-specific transcription factor and miRNA co-regulatory
474 networks," vol. 43, no. W1, pp. W283-W288, 2015.

- 475 45. D. Sengupta and S. J. M. B. Bandyopadhyay, "Participation of microRNAs in human
476 interactome: extraction of microRNA–microRNA regulations," vol. 7, no. 6, pp. 1966-1973,
477 2011.
- 478 46. D. Szklarczyk, A. Franceschini, S. Wyder, K. Forslund, D. Heller, J. Huerta-Cepas, M.
479 Simonovic, A. Roth, A. Santos and K. P. J. N. a. r. Tsafou, "STRING v10: protein–protein
480 interaction networks, integrated over the tree of life," vol. 43, no. D1, pp. D447-D452, 2015.
- 481 47. Z. Tang, C. Li, B. Kang, G. Gao, C. Li and Z. J. N. a. r. Zhang, "GEPIA: a web server for
482 cancer and normal gene expression profiling and interactive analyses," vol. 45, no. W1, pp.
483 W98-W102, 2017.
- 484 48. C. M. Ferreira, I. S. Pinto, E. V. Soares and H. M. J. R. A. Soares, "(Un) suitability of the use
485 of pH buffers in biological, biochemical and environmental studies and their interaction with
486 metal ions—a review," vol. 5, no. 39, pp. 30989-31003, 2015.
- 487 49. W. Ji, B. Sun and C. J. G. Su, "Targeting microRNAs in cancer gene therapy," vol. 8, no. 1,
488 pp. 21, 2017.
- 489 50. X. Xu, Y. Tao, L. Shan, R. Chen, H. Jiang, Z. Qian, F. Cai, L. Ma and Y. J. J. o. C. Yu, "The
490 role of MicroRNAs in hepatocellular carcinoma," vol. 9, no. 19, pp. 3557, 2018.
- 491 51. T. Ahmadzade, G. Reid and D. R. J. B. r. McKenzie, "Fundamentals of siRNA and miRNA
492 therapeutics and a review of targeted nanoparticle delivery systems in breast cancer," vol. 10, no.
493 1, pp. 69-86, 2018.
- 494 52. H. A. Seo, S. Moeng, S. Sim, H. J. Kuh, S. Y. Choi and J. K. J. C. Park, "MicroRNA-based
495 combinatorial cancer therapy: effects of MicroRNAs on the efficacy of anti-cancer therapies,"
496 vol. 9, no. 1, pp. 29, 2020.
- 497 53. I. Lee, S. S. Ajay, J. I. Yook, H. S. Kim, S. H. Hong, N. H. Kim, S. M. Dhanasekaran, A. M.
498 Chinnaiyan and B. D. J. G. r. Athey, "New class of microRNA targets containing simultaneous
499 5'-UTR and 3'-UTR interaction sites," vol. 19, no. 7, pp. 1175-1183, 2009.
- 500 54. X. Qi, D.-H. Zhang, N. Wu, J.-H. Xiao, X. Wang and W. J. J. o. m. g. Ma, "ceRNA in
501 cancer: possible functions and clinical implications," vol. 52, no. 10, pp. 710-718, 2015.
- 502 55. L. Ding, Z. Lan, X. Xiong, H. Ao, Y. Feng, H. Gu, M. Yu and Q. J. I. j. o. m. s. Cui, "The
503 dual role of microRNAs in colorectal cancer progression," vol. 19, no. 9, pp. 2791, 2018.
- 504 56. P. Costa-Pinheiro, J. Ramalho-Carvalho, F. Q. Vieira, J. Torres-Ferreira, J. Oliveira, C. S.
505 Gonçalves, B. M. Costa, R. Henrique and C. J. C. e. Jerónimo, "MicroRNA-375 plays a dual role
506 in prostate carcinogenesis," vol. 7, no. 1, pp. 1-14, 2015.
- 507 57. C. Yang, S. N. Tabatabaei, X. Ruan, P. J. C. P. Hardy and Biochemistry, "The dual
508 regulatory role of MiR-181a in breast cancer," vol. 44, no. 3, pp. 843-856, 2017.